Syndax - About the company
Syndax is a public company based in Waltham (United States), founded in 2005. It operates as a Developer of targeted therapies for the treatment of cancer. Syndax has raised $198M in funding from investors like Fidelity Investments, Avalon Ventures and Domain Associates. The company has 3277 active competitors, including 1125 funded and 779 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio.
Company Details
Developer of targeted therapies for the treatment of cancer. The company is developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma and triple negative breast cancer.
- Website
- syndax.com
- Social
- Registered Address
- Waltham, Massachusetts
Key Metrics
Founded Year
2005
Location
Waltham, United States
Stage
Public
Total Funding
$198M in 11 rounds
Latest Funding Round
Investors
Ranked
6th among 3277 active competitors
Annual Revenue
$100M - $500M as on Dec 31, 2025
Employee Count
336 as on Jun 30, 2026
Similar Companies
Exit Details
Public
Legal entities associated with Syndax
Syndax is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Syndax Pharmaceuticals, Inc. CIN: 320162505 , United States, Active | Dec 26, 999 | - | 268 (As on Dec 31, 2024) | - |
SYNDAX PHARMACEUTICALS INC CIN: 1395937 , United States, Active | Oct 10, 2005 | $100M - $500M (As on Dec 31, 2025) | 184 (As on Dec 31, 2024) | - |
Syndax's IPO details
Syndax got listed on Mar 03, 2016.
Click here to take a look at Syndax's IPO in detail
Sign up to download Syndax's company profile
Syndax's funding and investors
Syndax has raised a total funding of $198M over 11 rounds. Its first funding round was on Apr 03, 2007. Syndax has 21 institutional investors.
Here is the list of recent funding rounds of Syndax:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 31, 2020 | 2968181 | Post IPO | 7457809 | 5883347 | 5881623 | 5970451 |
Aug 28, 2015 | 9538364 | Series C | 1611179 | 4843827 | 9403818 | |
Jun 15, 2015 | 6063158 | Series B | 2337786 | 9046286 | 4765351 | 5527839 |
Access funding benchmarks and valuations. Sign up today!View details of Syndax's funding rounds and investors
Syndax's founders and board of directors
Founder? Claim ProfileSyndax's employee count trend
Syndax has 336 employees as of Jun 26. Here is Syndax's employee count trend over the years:
Uncover Syndax's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Syndax's Competitors and alternates
Top competitors of Syndax include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of Syndax, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 75/100 | |
3rd | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 72/100 | |
5th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
6th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
7th | Karyopharm 2008, Newton (United States), Public | Biopharmaceutical company focused on developing and commercializing innovative cancer therapies | $98.4M | 71/100 | |
8th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 71/100 | |
9th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
10th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Syndax's competitors? Click here to see the top ones
Syndax's Investments and acquisitions
Syndax has made no investments or acquisitions yet.
Reports related to Syndax
Here is the latest report on Syndax's geography:
News related to Syndax
Filter this listMedia has covered Syndax for a total of 16 events in the last 1 year, 11 of them have been about company updates and 1 about people movement.
•
Syndax Pharmaceuticals Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026GlobeNewswire•May 21, 2026•Syndax
•
Syndax Pharmaceuticals Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026GlobeNewswire•May 12, 2026•Syndax
•
Keybank Makes New $2.31 Million Investment in Syndax PharmaceuticalsMarketBeat•Feb 03, 2026•Syndax, KeyBank
•
Syndax and World Orphan Drug Alliance Launch Accessibility Program for Revuforj Outside the USGlobeNewswire•Jan 07, 2026•Syndax
•
•
•
•
Syndax Announces FDA Approval of Revuforj for R/R NPM1 Mutated Acute Myeloid LeukemiaGlobeNewswire•Oct 24, 2025•FDA, Syndax
•
Syndax's Revuforj® included in NCCN Clinical Practice Guidelines for AML treatmentGlobeNewswire•Sep 19, 2025•Syndax
•
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire•Sep 06, 2025•Syndax
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Syndax
Explore our recently published companies
- Autocal - Thane based, 2002 founded, Funding Raised company
- Indo Amines - Thane based, 1994 founded, Public company
- Taro International - Haifa based, 1992 founded, Unfunded company
- SmartCart AI - San Francisco based, Unfunded company
- 365 Retail Markets - London based, 2008 founded, Unfunded company
- Bishop Paiute Development Corporation - Bishop based, 2009 founded, Funding Raised company
